Article Versions Notes

Cox F, Saeland E, Thoma A, van den Hoogen W, Tettero L, Drijver J, Vaneman C, van Polanen Y, Ritschel T, Bastian AR, et al. RSV A2-Based Prefusion F Vaccine Candidates Induce RSV A and RSV B Cross Binding and Neutralizing Antibodies and Provide Protection against RSV A and RSV B Challenge in Preclinical Models. Vaccines. 2023; 11(3):672. https://doi.org/10.3390/vaccines11030672

Cox, Freek, Eirikur Saeland, Anne Thoma, Ward van den Hoogen, Lisanne Tettero, Joke Drijver, Cornelis Vaneman, Yolinda van Polanen, Tina Ritschel, Arangassery Rosemary Bastian, and et al. 2023. "RSV A2-Based Prefusion F Vaccine Candidates Induce RSV A and RSV B Cross Binding and Neutralizing Antibodies and Provide Protection against RSV A and RSV B Challenge in Preclinical Models" Vaccines 11, no. 3: 672. https://doi.org/10.3390/vaccines11030672

Cox, F., Saeland, E., Thoma, A., van den Hoogen, W., Tettero, L., Drijver, J., Vaneman, C., van Polanen, Y., Ritschel, T., Bastian, A. R., Callendret, B., Zahn, R., & van der Fits, L. (2023). RSV A2-Based Prefusion F Vaccine Candidates Induce RSV A and RSV B Cross Binding and Neutralizing Antibodies and Provide Protection against RSV A and RSV B Challenge in Preclinical Models. Vaccines, 11(3), 672. https://doi.org/10.3390/vaccines11030672